SI-BONE, Inc. (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 3,905 Shares

SI-BONE, Inc. (NASDAQ:SIBN) insider Anthony J. Recupero sold 3,905 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.84, for a total transaction of $54,045.20. Following the completion of the sale, the insider now owns 238,804 shares in the company, valued at $3,305,047.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

SI-BONE Stock Performance

Shares of NASDAQ:SIBN traded down $0.14 on Tuesday, hitting $14.18. 234,859 shares of the company were exchanged, compared to its average volume of 400,173. The company’s 50 day moving average price is $14.13 and its two-hundred day moving average price is $15.50. The firm has a market capitalization of $591.16 million, a price-to-earnings ratio of -13.01 and a beta of 1.20. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 9.17. SI-BONE, Inc. has a one year low of $11.76 and a one year high of $23.25.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The company had revenue of $39.97 million during the quarter, compared to the consensus estimate of $38.95 million. During the same quarter last year, the company earned ($0.30) EPS. Research analysts expect that SI-BONE, Inc. will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On SI-BONE

Several institutional investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new position in SI-BONE in the 2nd quarter valued at $61,000. Amalgamated Bank lifted its position in SI-BONE by 12.9% during the 4th quarter. Amalgamated Bank now owns 5,877 shares of the company’s stock worth $123,000 after buying an additional 673 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in SI-BONE by 14.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company’s stock worth $179,000 after acquiring an additional 1,106 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after acquiring an additional 2,108 shares in the last quarter. Finally, Arizona State Retirement System increased its position in SI-BONE by 7.7% in the 4th quarter. Arizona State Retirement System now owns 10,675 shares of the company’s stock valued at $224,000 after acquiring an additional 762 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SIBN has been the topic of a number of recent research reports. Truist Financial decreased their target price on SI-BONE from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Morgan Stanley reduced their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC dropped their target price on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of SI-BONE in a report on Tuesday, May 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.